Visit
VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas
VJHemOnc is pleased to bring you a feature exploring the emerging applications of MRD in multiple myeloma.
VJHemOnc is pleased to bring you a feature exploring the latest advances and developments in novel agents for MDS, with…
VJHemOnc is pleased to bring you a feature exploring the latest thinking on the application of MRD in AML trials…
VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…
VJHemOnc is pleased to bring you a feature exploring the latest developments in the treatment of NHL, with leading experts…
On August 24 2022, the European Medicines Agency (EMA) approved the use of teclistamab for the treatment of patients with…
On August 17 2022, the US Food and Drug Administration (FDA) approved the first cell-based gene therapy, betibeglogene autotemcel (beti-cel),…
VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…
VJHemOnc is excited to bring you the latest research updates in myeloid malignancies from the EHA 2022 Congress, which took…
Axicabtagene ciloleucel (axi-cel) was approved by the FDA in October 2017 for patients with large B-cell lymphoma (LBCL) after two…
VJHemOnc is excited to bring you a feature covering current challenges and future outlooks in amyloidosis.
Learn about the importance of performing genomic testing in CLL and how this impacts diagnosis, prognosis and treatment decisions.
The U.S. Food and Drug Administration (FDA) has approved the use of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed chimeric antigen receptor…
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter